Atlas Trials

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Clinical trial NCT03009058 · TERMINATED

Trial details

NCT number
NCT03009058
Sponsor
Immodulon Therapeutics Ltd
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Cancer
Start date
2017-05-31
Primary completion
2017-08-30
Enrollment
2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.